New anti-diabetic drugs like glucagon-like peptide 1 (GLP-1) agonists acting as anti-obesity drugs, have shown promising results in adults with MAFLD to reduce hepatic steatosis and liver enzyme activity [80]. Here, GCG is linked to fatty liver disease.